| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Pediatric Autoimmune Encephalopathy/CNS Disorder Evaluation, Serum
MessageSendout, Mayo test code: PCDES
Test Code
LAB155105
Alias/See Also
Encephalitis
Myelitis
Encephalopathy
Myelopathy, pediatric
Myelopathy, child
PCDES
Myelitis
Encephalopathy
Myelopathy, pediatric
Myelopathy, child
PCDES
CPT Codes
86341, 86363, 86053, 86255x10
Includes
If the indirect immunofluorescence assay (IFA) pattern suggests antineuronal nuclear antibody type 1 (ANNA-1), then ANNA-1 immunoblot, ANNA-1 IFA titer and ANNA-2 immunoblot will be performed at an additional charge.
If the IFA pattern suggests Purkinje cytoplasmic antibody (PCA)-Tr , then PCA-Tr immunoblot and PCA-Tr IFA titer will be performed at an additional charge.
If N-methyl-D-aspartate receptor (NMDA-R) antibody cell binding assay (CBA) is positive, then NMDA-R IFA titer will be performed at an additional charge.
If gamma-aminobutyric acid B receptor (GABA-B-R) antibody CBA is positive, then GABA-B-R IFA titer will be performed at an additional charge.
If the IFA pattern suggests dipeptidyl-peptidase-like protein-6 (DPPX) antibody, then DPPX antibody CBA and DPPX IFA titer will be performed at an additional charge.
If the IFA pattern suggests metabotropic glutamate receptor 1 (mGluR1) antibody, then mGluR1 antibody CBA and mGluR1 IFA titer will be performed at an additional charge.
If the IFA pattern suggests glial fibrillary acidic protein (GFAP) antibody, then GFAP antibody CBA and GFAP IFA titer will be performed at an additional charge.
If the neuromyelitis optica/aquaporin-4-IgG (NMO/AQP4-IgG) fluorescence-activated cell sorting (FACS) screen assay requires further investigation, then NMO/AQP4-IgG FACS titration assay will be performed at an additional charge.
If the myelin oligodendrocyte glycoprotein (MOG) FACS screen assay requires further investigation, then MOG FACS titration assay will be performed at an additional charge.
If IFA pattern suggests neurochondrin antibody, then neurochondrin antibody CBA and neurochondrin IFA titer will be performed at an additional charge.
If the IFA pattern suggests Purkinje cytoplasmic antibody (PCA)-Tr , then PCA-Tr immunoblot and PCA-Tr IFA titer will be performed at an additional charge.
If N-methyl-D-aspartate receptor (NMDA-R) antibody cell binding assay (CBA) is positive, then NMDA-R IFA titer will be performed at an additional charge.
If gamma-aminobutyric acid B receptor (GABA-B-R) antibody CBA is positive, then GABA-B-R IFA titer will be performed at an additional charge.
If the IFA pattern suggests dipeptidyl-peptidase-like protein-6 (DPPX) antibody, then DPPX antibody CBA and DPPX IFA titer will be performed at an additional charge.
If the IFA pattern suggests metabotropic glutamate receptor 1 (mGluR1) antibody, then mGluR1 antibody CBA and mGluR1 IFA titer will be performed at an additional charge.
If the IFA pattern suggests glial fibrillary acidic protein (GFAP) antibody, then GFAP antibody CBA and GFAP IFA titer will be performed at an additional charge.
If the neuromyelitis optica/aquaporin-4-IgG (NMO/AQP4-IgG) fluorescence-activated cell sorting (FACS) screen assay requires further investigation, then NMO/AQP4-IgG FACS titration assay will be performed at an additional charge.
If the myelin oligodendrocyte glycoprotein (MOG) FACS screen assay requires further investigation, then MOG FACS titration assay will be performed at an additional charge.
If IFA pattern suggests neurochondrin antibody, then neurochondrin antibody CBA and neurochondrin IFA titer will be performed at an additional charge.
Preferred Specimen
4 mL serum from a red tube
Patient Preparation
1. For optimal antibody detection, specimen collection is recommended prior to initiation of immunosuppressant medication or intravenous immunoglobulin treatment.
2. This test should not be requested for patients who have recently received radioisotopes, therapeutically or diagnostically, because of potential assay interference. The specific waiting period before specimen collection will depend on the isotope administered, the dose given, and the clearance rate in the individual patient. Specimens will be screened for radioactivity prior to analysis. Radioactive specimens received in the laboratory will be held 1 week and assayed if sufficiently decayed or canceled if radioactivity remains.
Minimum Volume
2 mL
Other Acceptable Specimens
Serum gel tube
Instructions
Centrifuge and aliquot serum into a plastic vial.
Transport Container
Plastic vial
Transport Temperature
Refrigerated
Specimen Stability
Refrigerated (preferred): 28 days
Frozen: 28 days
Ambient: 72 hours
Frozen: 28 days
Ambient: 72 hours
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis: Reject
Gross lipemia: Reject
Gross icterus: Reject
Gross lipemia: Reject
Gross icterus: Reject
Methodology
CS2CS, DPPCS, GABCS, GFACS, LG1CS, GL1CS, NCDCS, NMDCS: Cell Binding Assay (CBA)
MOGFS, MOGTS, NMOFS, NMOTS: Flow Cytometry
ANN1S, AN1TS, DPPIS, DPPTS, GABIS, GFAIS, GFATS, GL1IS, GL1TS, NCDIS, NCDTS, NMDIS, PCATR, PCTTS: Indirect Immunofluorescence (IFA)
GD65S: Radioimmunoassay (RIA)
AN1BS, AN2BS, PCTBS: Immunoblot (IB)
FDA Status
Approved
Setup Schedule
Profile tests: Monday through Sunday
Reflex tests: Varies
Reflex tests: Varies
Report Available
8-12 days
Limitations
Test for patients under 18 years of age. For adults, order Mayo test code: ENS2.
Reference Range
Included with report
Clinical Significance
Evaluating children with autoimmune central nervous system disorders using serum specimens
Performing Laboratory
Mayo Clinic Laboratories, Rochester, Minnesota
Additional Information
Pediatric Autoimmune Encephalopathy/CNS Disorder Evaluation, Serum
